Figure 1. Research Method Flow Chart 9
Figure 2. Breakdown of Primary Research 11
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 13
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 15
Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, $ mn 17
Figure 6. Impact of COVID-19 on Business 18
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market 20
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 23
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 23
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market 24
Figure 11. Investment Opportunity Analysis 28
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Influenza Treatment Market 31
Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 35
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 36
Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 37
Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 38
Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, $ mn 39
Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 40
Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 41
Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 42
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 43
Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, $ mn 44
Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, $ mn 45
Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, $ mn 46
Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 47
Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 48
Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 49
Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 50
Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 51
Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 52
Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 53
Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 54
Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, $ mn 55
Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, $ mn 56
Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 58
Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 59
Figure 37. Influenza Treatment Market in Japan, 2019-2030, $ mn 61
Figure 38. Influenza Treatment Market in China, 2019-2030, $ mn 63
Figure 39. Influenza Treatment Market in Australia, 2019-2030, $ mn 65
Figure 40. Influenza Treatment Market in India, 2019-2030, $ mn 67
Figure 41. Influenza Treatment Market in South Korea, 2019-2030, $ mn 69
Figure 42. Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn 71
Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period 73
Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic. Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country. Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs Based on Influenza Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More